nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying
|
Marathe, Chinmay S. |
|
|
13 |
6 |
p. 1245-1249 |
artikel |
2 |
Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
|
Schnaars, Yvonne |
|
|
13 |
6 |
p. 1215-1229 |
artikel |
3 |
Correction to: Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria
|
Di Loreto, Chiara |
|
|
13 |
6 |
p. 1251 |
artikel |
4 |
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK
|
McCrimmon, Rory J. |
|
|
13 |
6 |
p. 1203-1214 |
artikel |
5 |
Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial
|
Yan, Xiang |
|
|
13 |
6 |
p. 1161-1174 |
artikel |
6 |
Measuring the Impact of Flash Glucose Monitoring in a Pediatric Population in Saudi Arabia: A Retrospective Cohort Study
|
Alharbi, Mohammed Y. |
|
|
13 |
6 |
p. 1139-1146 |
artikel |
7 |
Oral Semaglutide: Dosage in Special Situations
|
Kalra, Sanjay |
|
|
13 |
6 |
p. 1133-1137 |
artikel |
8 |
Profile of Patients with Diabetes Treated with Insulin Lispro 200 U/ml: A Real-World Study from Spain
|
Rubio de Santos, Miriam |
|
|
13 |
6 |
p. 1147-1160 |
artikel |
9 |
Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study
|
Galstyan, Gagik R. |
|
|
13 |
6 |
p. 1187-1202 |
artikel |
10 |
Reductions in HbA1c with Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-Analysis of 75 Real-World Observational Studies
|
Evans, Mark |
|
|
13 |
6 |
p. 1175-1185 |
artikel |
11 |
Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN)
|
Guo, Lixin |
|
|
13 |
6 |
p. 1231-1244 |
artikel |